1-cycloheptyl-4-hydroxymethyl-3,3-dimethyl-pyrrolidin-2-one | 915378-63-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-cycloheptyl-4-hydroxymethyl-3,3-dimethyl-pyrrolidin-2-one
• 英文别名: 1-cycloheptyl-4-(hydroxymethyl)-3,3-dimethylpyrrolidin-2-one
• CAS: 915378-63-1
• 化学式: C₁₄H₂₅NO₂
• 分子量: 239.358
• InChiKey: KPVCORADBRNCHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-cycloheptyl-4-hydroxymethyl-3,3-dimethyl-pyrrolidin-2-one 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 1-cycloheptyl-4,4-dimethyl-5-oxo-pyrrolidine-3-carbaldehyde
  参考文献：
  名称：

  WO2007/118185

  摘要：

  公开号：
• 作为产物：
  描述：

  4-(tert-butyl-dimethyl-silanyloxymethyl)-1-cycloheptyl-3,3-dimethyl-pyrrolidin-2-one 在 盐酸 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以100%的产率得到1-cycloheptyl-4-hydroxymethyl-3,3-dimethyl-pyrrolidin-2-one
  参考文献：
  名称：

  Discovery of orally active butyrolactam 11β-HSD1 inhibitors

  摘要：

  A series of metabolically stable butyrolactam 11 beta-HSD1 inhibitors have been synthesized and biologically evaluated. These compounds exhibit excellent HSD1 potency and HSD2 selectivity, pharmacokinetic, and pharmacodynamic profiles. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.034

文献信息

• INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME
  申请人：Yeh S. Vince

  公开号：US20080076819A1

  公开（公告）日：2008-03-27

  A compound of formula (I): or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Methods of inhibiting 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Methods of treating non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

  化合物式(I)的复合物，或其药学上可接受的盐、前药、前药的盐或其组合物。抑制11-β-羟基类固醇脱氢酶1型酶的方法。治疗非胰岛素依赖性2型糖尿病、胰岛素抵抗、肥胖症、脂质代谢紊乱、代谢综合征和其他由过度糖皮质激素作用介导的疾病和情况的方法。
• Inhibitors of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Enzyme
  申请人：Yeh Vince S.

  公开号：US20080312214A1

  公开（公告）日：2008-12-18

  Methods for treating a mammal suffering from glucocorticoid-related diseases and conditions, comprising administering to the mammal an effective amount of a selective inhibitor of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme activity, wherein the inhibitor is a compound of formula (I): or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Methods of inhibiting 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Methods of treating neuronal degeneration, dysfunction, acute psychosis, anxiety, dementia, depression, non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

  治疗患有糖皮质激素相关疾病和症状的哺乳动物的方法，包括向哺乳动物施用有效量的11-β-羟基类固醇脱氢酶类型1酶活性的选择性抑制剂，其中该抑制剂是式(I)的化合物，或其药学上可接受的盐、前药盐、前药盐的盐或其组合。抑制11-β-羟基类固醇脱氢酶类型1酶的方法。治疗神经退行性、功能障碍、急性精神病、焦虑、痴呆、抑郁、非胰岛素依赖型2型糖尿病、胰岛素抵抗、肥胖症、脂质代谢紊乱、代谢综合症以及其他由过度糖皮质激素作用介导的疾病和症状的方法。
• Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
  申请人：Abbott Laboratories

  公开号：US07737137B2

  公开（公告）日：2010-06-15

  Methods for treating a mammal suffering from glucocorticoid-related diseases and conditions, comprising administering to the mammal an effective amount of a selective inhibitor of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme activity, wherein the inhibitor is a compound of formula (I): or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Methods of inhibiting 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Methods of treating neuronal degeneration, dysfunction, acute psychosis, anxiety, dementia, depression, non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

  治疗患有糖皮质激素相关疾病和病况的哺乳动物的方法，包括向哺乳动物施用有效量的11-β-羟基类固醇脱氢酶类型1酶活性的选择性抑制剂，其中抑制剂是化合物I的药物接受性盐、前药、前药的盐或其组合。抑制11-β-羟基类固醇脱氢酶类型1酶的方法。治疗神经退行性、功能障碍、急性精神病、焦虑、痴呆、抑郁、非胰岛素依赖性2型糖尿病、胰岛素抵抗、肥胖症、脂质代谢紊乱、代谢综合征和其他由过度糖皮质激素作用介导的疾病和病况的方法。
• US7435833B2
  申请人：——

  公开号：US7435833B2

  公开（公告）日：2008-10-14
• US7737137B2
  申请人：——

  公开号：US7737137B2

  公开（公告）日：2010-06-15